T he World Health Organization estimates that diabetes mellitus (DM) affects 220 million people worldwide and that number is projected to double by 2030 (1) . DM predisposes to a large number of other diseases, such as cardiovascular disease, infection, and renal failure. It is therefore unsurprising that patients with DM form 23%-30% of the published cohorts of critically ill patients (2, 3) .
The influence of DM on outcomes in the critically ill patient is uncertain. Some studies have reported that DM increases mortality (2, 4) , some that DM decreases mortality (5) (6) (7) , and some that the risk is neutral (3, (8) (9) (10) . Acute lung injury (ALI) is a common complication on the intensive care unit (ICU) and occurs in 30% of critically ill patients, with an estimated mortality of up to 60% (11) . Of interest, previous studies have shown that patients with DM appear to have a lower prevalence of ALI or acute respiratory distress syndrome (12, 13 ) (a syndrome of hypoxia and lung edema not secondary to left heart failure) (14) .
Multiple reasons have been proposed to explain why DM may protect against ALI/acute respiratory distress syndrome, including the effect of hyperglycemia on the host response (15) , and in this study we elected to look specifically at the role of medication prescribed to patients with DM. A number of preadmission drug treatments have also been postulated to Objectives: Patients with diabetes mellitus form 23%-30% of published cohorts of critically ill patients. Conflicting published evidence links diabetes mellitus to both higher and lower mortality. Other cohort studies suggest that diabetes mellitus protects against acute lung injury. We hypothesized that diabetes mellitus is an independent risk factor for mortality. We further hypothesized that diabetes mellitus is a risk factor for cardiac overload and not for acute lung injury.
Design: retrospective cohort study. Setting: The intensive care unit of a tertiary referral hospital.
Patients: From November 1, 2004, to October 1, 2007, a cohort of patients admitted ≥48 hrs to the intensive care unit.
Interventions: None. Measurements and Main Results: Of 2,013 patients, 317 had diabetes mellitus. Ninety-day mortality was higher in the diabetes mellitus patients compared to patients without diabetes mellitus (hazard ratio 1.53, 95% confidence interval 1. 29-1.80 ). This association strengthened after adjusting for confounders and for medication (hazard ratio 1.53, 95% confidence interval 1.07-2.17).We found no association between diabetes mellitus and acute lung injury (relative risk ratio 1.01, 95% confidence interval 0.78-1.32; adjusted relative risk ratio 0.99, 95% confidence interval 0.75-1.31), but diabetes mellitus was a risk factor for cardiac overload (relative risk ratio 1.91, 95% confidence interval 1.30-2.81; adjusted relative risk ratio 1.45, 95% confidence interval 0.97-2.18). Statins were associated with both a reduced risk of mortality (hazard ratio 0.74, 95% confidence interval 0.63-0.87; adjusted hazard ratio 0.53, 95% confidence interval 0.44-0.64) and a decreased risk of developing acute lung injury (relative risk ratio 0.71, 95% confidence interval 0.56-0.89; adjusted relative risk ratio 0.61, 95% confidence interval 0.47-0.79).
Conclusions: Diabetes mellitus is an independent risk factor for mortality in critically ill patients and failure to adjust for statins underestimates the size of this association. Diabetes mellitus is not associated with acute lung injury but is associated with cardiac overload. A diagnosis of cardiac overload excludes a diagnosis of acute lung injury. Investigators who do not account for cardiac overload as a competing alternative outcome may therefore falsely conclude that diabetes mellitus protects from acute lung injury. (Crit Care Med 2012; 40: 1835-1843) Key WOrDS: acute lung injury; acute respiratory distress syndrome; confounding factors (epidemiology); Cox regression; diabetes mellitus; heart failure; hydroxymethylglutaryl-CoA reductase inhibitors; intensive care; mortality; multinomial logistic regression in the critically ill patient, diabetes predicts mortality independent of statin therapy but is not associated with acute lung injury: a cohort study* influence mortality or the development of ALI in observational human or animal studies, most notably statins (16) (17) (18) , angiotensin converting enzyme inhibitors (19, 20) , and angiotensin II receptor inhibitors (21) . We also considered the possibility of biases introduced by analysis techniques: the diagnoses of ALI and cardiac overload (CO) are mutually exclusive, and patients with DM are more prone to ischemic heart disease and consequently CO (22) . We considered the possibility that patients with DM who do not suffer from ALI may die of CO instead.
In this study, we investigated the influence of DM on mortality and hypothesized that any protective effect might be conferred by medication taken by patients with DM and not due to DM itself. We examined this question using data from a previously published cohort (23) , with 90-day mortality as the primary outcome and ALI as a secondary end point. We included CO as a secondary end point, the diagnosis of which excludes the diagnosis of ALI.
MATERIALS AND METHODS
Cohort. We examined a cohort of 2,024 intensive care patients (previously described by Vlaar et al (23)). In brief, this is a cohort of consecutive adult patients (aged 18 yrs) admitted >48 hrs to the ICU of the Academic Medical Center, Amsterdam, over the period November 1, 2004 , to October 1, 2007 . Readmissions were excluded.
The primary outcome measure was mortality (28-day and 90-day) verified against the National Dutch registry of deaths; this was therefore missing only when subjects had left the country. Secondary outcomes were ALI and CO. ALI was defined using the consensus definition of Bernard et al (24) (acute onset; bilateral interstitial infiltrates on chest radiography; pulmonary-artery wedge pressure <18 mm Hg or lack of left atrial hypertension; and PaO 2 :FIO 2 <300). Pulmonary edema was diagnosed as being of cardiogenic origin if the pulmonary arterial occlusion pressure was 18 mm Hg. In the absence of pulmonary artery wedge catheter measurements, cardiac failure was diagnosed if two of the following were present: central venous pressure15 mm Hg, a history of heart failure or valve dysfunction, ejection fraction 45% as estimated by echocardiogram, or a positive fluid balance. The probability of cardiogenic pulmonary edema was scored by two physicians independently on a scale of 1-4 (A.P.J.V. and N.P.J.) (25) . Chest radiographs were score by two physicians inde pendently (A.P.J.V. and N.P.J.), with disagreements resolved by a radiologist. In the Netherlands, the National Intensive Care Evaluation has prospectively collected data on severity, length of stay, and mortality for all intensive care patients since 2002 (26, 27) . Information was collected on alcohol abuse, liver failure, DM, hematological malignancy, chronic obstructive pulmonary disease, autoimmune disease, immune compromise, massive transfusion, surgery, pancreatitis, pneumonia, and sepsis. DM was specifically scored as a history of DM diagnosed prior to admission.
Details of drug treatment (sulphonylureas, metformin, thiazolidinediones, HMG CoAreductase antagonists [statins], angiotensin converting enzyme inhibitors, and angiotensin II receptor inhibitors) were obtained by review of the patient's notes or by telephoning the patient's general practitioner when this was missing. No drug history was obtained for patients admitted 48 hrs. Immunosuppression was defined as prednisolone treatment ≥30 mg/day (or the equivalent dose of corticosteroid), therapy with azathioprine, methotrexate, cyclosporin, or rapamycin; HIV infection with a CD4 count was 200 cells/mm 3 , or a neutrophil count 1.0 × 10 9 cells/L prior to admission.
Statistical Analysis. Ninety-day mortality was the primary outcome of interest, and survival was analyzed by Kaplan-Meier methods. Mortality was also examined at 28 days and 1 yr, but these were of secondary interest. Secondary outcomes examined were ALI, CO, and No ALI/No CO. DM was the main exposure of interest. The effect of DM on mortality was explored using Cox regression models; the effect of DM on ALI, CO, and No ALI/No CO were explored using multinomial logistic regression, because no data were available for time of onset. We sought to avoid over adjustment bias and unnecessary adjustment (28) by identifying confounders using a conceptual hierarchical framework/directed acyclic graph (see details in Supplementary Fig. 1 , Supplemental Digital Content 2, http://links. lww.com/CCM/A452) laid out using Cytoscape 2.8.1 (29) and not by p values or likelihood ratio tests (30) (31) (32) .
Ethics. The study was approved by the Medical Ethics Committee of the Academic Medical Center, Amsterdam, The Netherlands (reference 08.17.0964), who waived the requirement for individual informed consent in view of the retrospective nature of this research.
RESULTS
Over the course of the study period, 5,208 patients were admitted, of whom 2013 were included in the final study, with a mean of 1.98 yrs of follow-up per person ( Fig. 1 ). In this cohort, there were a total of 317 patients with DM diagnosed prior to admission vs. 1,696 without.
The characteristics of study participants are described in Table 1 . Patients with DM were older than those without (median 68 yrs vs. 61 yrs, respectively, p  .001) and had a higher body mass Patients with DM were more likely to have had a myocardial infarction, present with sepsis or pancreatitis, and less likely to present with multiple trauma. They were also more likely to be admitted to ICU electively. Patients with DM were also more severely unwell (Simplified Acute Physiology Score II score 48 vs. 44, Acute Physiology and Chronic Health Evaluation II score 17 vs. 16).
We also compared the characteristics of survivors against nonsurvivors ( Table 2) . Patients who died were more likely to have DM, were older, and had a lower body mass index. They were more likely to have sepsis, liver failure, hematological malignancy, pneumonia, immune compromise, and autoimmune disease. They were less likely to present with multiple trauma. Nonsurvivors were less likely to be planned admissions and less likely to be surgical patients. They also tended to be more unwell at admission (median Simplified Acute Physiology Score II score 48 vs. 44; median Acute Physiology and Chronic Health Evaluation II score 17 vs. 16 ). Patients who died were more likely to have had either ALI or CO.
We compared the patients according to secondary outcomes, ALI and CO, and found multiple differences in risk factors that are described in Table 3 .
Effect of DM on Mortality and ALI. Mortality was higher in patients with DM at 28 days, 90 days, and at 1 yr (Table 1 ) and the hazard ratio (HR) for DM was 1.53 (Table 4 ). This dropped slightly to 1.46 after adjustment for confounders, but rose again to 1.53 in an exploratory analysis that adjusted for the effect of medication. Adjusting for Acute Physiology and Chronic Health Evaluation II score (which we argue is incorrect) dropped the HR to 1.43. DM patients were not at increased risk of ALI (relative risk ratio [RRR] 1.01), but were more likely to have CO (RRR 1.91). Adjustment for confounders did not change the risk of ALI (RRR 0.99), but did reduce slightly the risk of CO (RRR 1.45) ( Table 5 ). If one combined the CO patients with the No ALI/No CO patients, the odds ratio in DM fell to 0.92 (95% confidence interval [CI] 0.71-1.17).
We performed two further exploratory analyses for ALI and CO. In the first analysis, we found that the effect of DM on CO was further reduced after adjustment for the effect of medication and the CIs crossed 1 (RRR 1.32) ( Table 5 ). In the second analysis, we combined CO patients with No ALI patients and found that the odds ratio for ALI then fell to 0.92.
Effect of Medication on Mortality and ALI. Patients with DM were more likely to be taking statins, angiotensin converting enzyme-inhibitors, or angiotensin II receptor-inhibitors (Table 1 ).
There were also differences in the medication history of nonsurvivors compared to survivors. Nonsurvivors were more likely to be on cardiac sulfonylureas and less likely to be on statins ( Table 2) . Further differences were also found in ALI and CO patients ( Table 3 ). In this cohort, ALI patients were less likely to be taking statins, whereas CO patients were more likely to be on statins and angiotensin converting enzyme-inhibitors.
In the unadjusted Cox regression analysis (Table 6) , insulin, cardiac sulfonylureas, and metformin were associated with increased mortality. However, these associations disappeared after adjusting for confounders. Use of statins was associated with survival and this effect strengthened after adjustment for confounders.
Use of statins was also protective in the occurrence of ALI in the unadjusted multinomial logistic regression analysis ( Table 7) , an association which became stronger after adjusting for confounders. Use of metformin and insulin were associated with CO, but this effect disappeared in the multivariable analysis ( Table 7) .
DISCUSSION
In this cohort of 2,013 critically ill patients, we studied the relationship of DM with two outcomes: mortality and ALI. We found that DM was associated with mortality, but was unrelated to ALI. These results diverge from those in the published literature.
DM was associated with increased mortality (HR 1.53), and this effect persisted after adjusting for confounders (HR 1.47). The finding that DM increases the risk of mortality agrees with some studies (2, 4) but not all (3, (5) (6) (7) (8) (9) . We provide two possible explanations for these contrasting findings: the effect of medication and differences in the identification of confounders.
Our analysis was designed to distinguish between effects of DM and of medications, which are often prescribed to patients with DM. Adjustment for statin use increased the association between DM and mortality: patients with DM were more likely to be prescribed statins and this can be interpreted to mean the protective effect of statins was ameliorating the apparent detrimental effect of DM (HR for DM was 1.47 after adjustment for confounders, but 1.55 after adjusting for medication).
The protective effect of statins on mortality has been shown in multiple previous observational studies (16, 33) . Our adjusted estimate for statins on mortality (HR 0.53, 95% CI 0.44-0.64) is comparable to that reported by Janda et al (16) in a metaanalysis of 20 sepsis studies (30-day mortality odds ratio 0.61, 95% CI 0.48-0.73).
However, a study by Christensen et al (33) on 12,483 critically ill patients reported a higher HR of 0.76 (0.69-0.86) that is consistent with our unadjusted estimate.
Multiple mechanisms have been proposed for the effect of statins, including effects on cell signaling, alteration of leukocyte-endothelial cell interaction, and reduced major histocompatibility class II antigen expression (34) . We suggest that differences in prescribing practices may account for differences in the published studies of DM and mortality.
We have also demonstrated the bias that arises from over adjustment. In our data set, inappropriate adjustment for Acute Physiology and Chronic Health Evaluation II score resulted in an underestimate of the association between DM and mortality (HR fell from 1.53 to 1.43). In studies of DM and mortality where estimates have been inappropriately adjusted for severity, we propose that the unadjusted estimate may be more reliable.
The second outcome examined was ALI, and we found no association with DM in our study (RRR 1.01, adjusted RRR 0.99, Table 5 ). The effect of DM on ALI dropped after adjusting for medication (RRR 0.76) but the CI still crossed 1. The CIs for the first two estimates were entirely contained within the third, strongly suggesting that the three estimates are consistent with each other, even though the point estimate did drop.
The proportion of DM patients in the CO group (25.0%) was different from the other two groups (14.8% in the No ALI/ No CO group and 15.0% in the ALI group [ Table 3 ], p = .005). Combining the CO patients with the No ALI/No CO patients increased the proportion of DM patients in the comparator group and caused the unadjusted estimates for the effect of DM on ALI to fall from 1.01 to 0.92. This demonstrates that combining CO patients with No ALI/No CO does, in principle, bias the results toward an apparent protective effect. This bias would have been more severe had there been a larger proportion of cardiac failure patients in our cohort.
Two previous studies have shown a protective effect of DM on ALI/acute respiratory distress syndrome (12, 13) , but neither study accounted for the effect of medication or considered CO as an alternative outcome.
Our study has a number of limitations. First, Hb A1c measurements were not available, so patients with previously undiagnosed DM would be misclassified in the No DM group. The proportion of patients with DM in this study (15.7%) was lower than in other published studies (2, 3) , and this may be attributed to misclassification. If the misclassification is unrelated to DM severity, then our estimate of the effect of DM on mortality is closer to zero than the true value. If patients identified with DM have more severe DM than patients with DM misclassified as having No DM, then we overestimate the association between DM and mortality, but only if such an association already exists. The lack of HbA1c measurements also means that we have no data on the level of DM control in patients known to have DM . Second, we were unable to distinguish type 1 and 2 DM in our cohort, the pathogenesis of which are heterogenous. Third, patients were excluded if they stayed <48 hrs in the ICU because the cohort was originally designed to look for transfusion-related ALI, which is rare in patients who stay on the ICU for <48 hrs (35, 36) . ALI and CO may develop within 48 hrs of admission, but our study contains no information about these patients. Fourth, the golden standard for distinguishing between hydrostatic pulmonary edema (due to CO) and pulmonary edema secondary to increased vascular permeability (ALI) is to estimate protein leakage in bronchoalveolar lavage fluid, but this is not a routine clinical procedure and therefore not available retrospectively. Fifth, we may not have adjusted for unmeasured confounders, for instance, other common causes of DM and differences in preadmission medication.
The primary criticism of retrospective studies is the potential for recall bias regarding exposures of interest. Our data were not collected from interviews, so recall bias seems unlikely to be an issue. The cohort was originally formed to study transfusionrelated ALI, so observer bias in scoring the patients for DM and for cardiac risk factors also seems unlikely. Nevertheless, our results need to be validated by investigators using the same methods.
Our study has a number of strengths, one of which is the use of new epidemiological techniques to identify confounding. Observational studies are prone to confounding, and although statistical methods are available to adjust for confounding, inappropriate selection of parameters that are not true confounders may result in biases from overadjustment (adjustment for parameters on the causal pathway) or unnecessary adjustment (adjustment for irrelevant parameters [28] ).
This study confirms and extends previous observational evidence that statins protect from mortality (16, 17) and from ALI (18) . The retrospective nature of this study means that the drugs under study were all started prior to admission, and this study cannot provide guidance on whether they might be associated with benefits if given after admission. Evidence is currently awaited from randomizedcontrolled trials that initiating statins after admission produces similar benefits (ClinicalTrials.gov NCT00528580 and NCT00979121) and the routine use of statins to prevent ALI or mortality in the ICU cannot currently be recommended outside of the research setting.
CONCLUSIONS
DM is associated with increased mortality in the critically ill patient and this association is independent of preadmission drug therapy. We argue that in the Medication cannot be a confounder for diabetes mellitus because it lies on the causal pathway between diabetes mellitus and acute Lung Injury (ALI). This is therefore an exploratory analyses to look for potential mechanisms, and this estimate cannot be interpreted as being adjusted for confounders.
The comparator for all relative risk ratios (RRRs) was the No ALI/No cardiac overload (CO) group. RRRs between 0 and 1 indicate association with ALI or CO less than with No ALI/No CO. Values >1 indicate association with ALI or CO greater than in the patients with No ALI/No CO. RRRs close to 1 suggest no difference compared to patients with No ALI/No CO. The Hausman-McFadden test reported p > .99 for all models. context of DM studies, adjusting for severity is inappropriate and produces biased estimates that could be incorrectly interpreted as demonstrating no effect of DM on mortality.
We found no effect of DM on the prevalence of ALI, even after adjusting for confounders. We demonstrated that CO must be analyzed as an alternative competing outcome for ALI and that failure to do so leads to biased estimates.
Statin therapy may influence estimates for the effect of DM on outcomes and these effects need to be accounted for in studies of the effect of DM.
